Total Funding
25
79
Total FundingSeed raised
Growth Score
-3 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
55923
BlinkBio employs specialized Bioorthogonal chemistries for the delivery of next generation medicines.
Colin Goddard: Chairman and CEOPast Role: OSI Pharmaceuticals, CEO
Don Bergstrom: Co-founder
About the Company
BlinkBio is a biotechnology company formed to exploit Bioorthogonal Linker (“BLink”) chemistries through their Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. It has assembled a modular toolbox of components allowing the design of Tunable Drug Conjugates a new class of Drug Conjugate therapies for the
treatment of cancer. The company's TDC platform comprises a modular set of ligands, linkers, and payloads with aligned characteristics to enable both rapid payload release in the tumor and rapid systemic clearance of the parent drug conjugate.
It was founded in 2009 and is headquartered in Jupiter, Florida.
